Optimizing a therapy for opiate use disorders: Characterizing ondansetron pharmacokinetics in blood...
Optimizing a therapy for opiate use disorders: Characterizing ondansetron pharmacokinetics in blood and brain
About this item
Full title
Author / Creator
Publisher
United States: John Wiley & Sons, Inc
Journal title
Language
English
Formats
Publication information
Publisher
United States: John Wiley & Sons, Inc
Subjects
More information
Scope and Contents
Contents
Administration of a widely used 5‐hydroxytryptamine receptor (5HT3AR) antagonist (ondansetron) potently inhibited the development of experimentally induced opioid dependence and withdrawal responses in mice and humans. However, in several studies examining withdrawal symptoms in subjects with chronic opioid use disorders (OUDs), ondansetron exhibit...
Alternative Titles
Full title
Optimizing a therapy for opiate use disorders: Characterizing ondansetron pharmacokinetics in blood and brain
Authors, Artists and Contributors
Author / Creator
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_doaj_primary_oai_doaj_org_article_878793b4463b4d988722f3c647db24b7
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_doaj_primary_oai_doaj_org_article_878793b4463b4d988722f3c647db24b7
Other Identifiers
ISSN
1752-8054
E-ISSN
1752-8062
DOI
10.1111/cts.13440
